Mineralocorticoid receptor antagonist (MRA) use in UK heart failure care: a national primary care cohort study
MRAs are underused in people with HFrEF in the UK. Although prescribing increased between 2014 and 2020, half of the cohort still did not receive the therapy. Older age, gender, comorbidities and co-prescriptions were linked to MRA underuse. Understanding the factors contributing to underprescribing at a population level should be used to inform quality improvement strategies.
Authors
- Rory Maclean (ORCID: https://orcid.org/0000-0002-9686-0501)
- Anoop D Shah (ORCID: https://orcid.org/0000-0002-8907-5724)
- R Thomas Lumbers (ORCID: https://orcid.org/0000-0002-9077-4741)
- Yang Chen (ORCID: https://orcid.org/0000-0001-6032-3387)
Institutions
- University College London Hospitals NHS Foundation Trust (GB)
- UCL Biomedical Research Centre (GB)
- Farr Institute (GB)
- University College London (GB)
Publication Details
- Journal
- Heart
- Published
- 2025-04-18
- DOI
- https://doi.org/10.1136/heartjnl-2024-325132
- Citations
- 1
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- UK Research and Innovation
- NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
- National Institute for Health and Care Research
- British Heart Foundation
- Engineering and Physical Sciences Research Council